Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$7.27
EPS est.
$6.82
EPS surprise
+6.57%
1-day move
+0.06%
United Therapeutics reported better-than-expected earnings per share, which contributed to a slight increase in stock price. However, there was no revenue reported, and the lack of guidance leaves uncertainty about future performance. Investors may be cautiously optimistic based on the EPS beat, but the overall outlook remains unclear without additional context from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.27 | $7.03 | +6.57% |
| Revenue | — | $805M | — |
No transcript is on record, and the analysis is based on numerical results only.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative products to treat chronic and life-threatening conditions. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, particularly in pulmonary arterial hypertension and organ transplantation.
Last quarter
In Q1-2026, United Therapeutics reported an EPS of $5.82, which was below the expected $6.73, resulting in a 13.57% surprise. Following the earnings report, the stock rose by 4.29% the next day.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+1.88%
Avg 1-day reaction
+1.77%
Analysts are cautiously optimistic about United Therapeutics' upcoming earnings, expecting a rebound in EPS and revenue after a miss last quarter. The consensus estimates suggest a recovery in financial performance.
Bull case
If the company exceeds EPS expectations and shows strong revenue growth, it could signal a successful product pipeline and increased market confidence.
Bear case
Conversely, if the company misses estimates again, it may raise concerns about its growth prospects and ability to innovate, leading to a potential decline in stock value.
Key metrics to watch
EPS
$7.03Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$805MRevenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for sustaining operations and funding research.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $7.03?
A beat on EPS could restore investor confidence after last quarter's miss and indicate strong operational performance.
Q2
What revenue growth will be reported compared to the consensus of $805M?
Revenue growth is critical for assessing the company's market position and ability to fund future innovations.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for a strong recovery in EPS and revenue, given the company's innovative pipeline and market position.
Supporting evidence
Options are pricing a 13.23% move, indicating expectations of significant volatility that may not align with the company's actual performance.
The recent history of earnings surprises suggests that the company has the potential to exceed expectations more often than not.
Key risk
If the company reports strong growth in its product pipeline, it could challenge the current consensus estimates.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it follows a disappointing earnings report, and investors are keen to see if the company can rebound.
Bull confirmed if
Exceeding the EPS estimate of $7.03 and achieving revenue above $805M would confirm the bull case.
Bear confirmed if
Falling short of both the EPS and revenue estimates would solidify the bear case.
What the market is pricing for the move.
Implied Move
±13.23%
Historical Avg
±5.8%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±13.2% while UTHR has averaged ±5.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
25.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$48.8M
93,800 sh
2 insiders
Net
$48.8M
Net selling
Most Active Insiders· 158 open-market trades
$44.1M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
99.99%
of float
Insider
2.00%
of float
Holders
1,210
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,294,529 sh · $2.9B
12.34%
-1.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If United Therapeutics beats expectations, history suggests the stock could rise by an average of 3.01% the next day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of around 2.71% based on historical patterns, raising concerns about the company's growth trajectory.
The lines on the call that would change the story.
$4.7M
Net selling
Recent Transactions
Sep 25, 2026 · @ $476.13
2,744 sh
$1.3M
Sep 24, 2026 · @ $470.63
2,603 sh
$1.2M
Oct 6, 2026 · @ $540.68
2,054 sh
$1.1M
Sep 29, 2026 · @ $478.10
2,309 sh
$1.1M
Sep 24, 2026 · @ $471.77
2,160 sh
$1.0M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Avoro Capital Advisors LLC
2,777,777 sh · $1.5B
6.48%
5.6%
Vanguard Portfolio Management LLC
1,919,429 sh · $1.0B
4.48%
-4.2%
Vanguard Capital Management LLC
1,918,256 sh · $1.0B
4.47%
-2.0%
State Street Corporation
1,898,064 sh · $1.0B
4.43%
2.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.